Cargando…
Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19
GS‐441524, the parent nucleoside of remdesivir, has been proposed to be effective against Covid‐19 based on in vitro studies and studies in animals. However, randomized clinical trials of the agent to treat Covid‐19 have not been conducted. Here, we evaluated GS‐441524 for Covid‐19 treatment based o...
Autores principales: | Rasmussen, Henrik Berg, Thomsen, Ragnar, Hansen, Peter Riis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994193/ https://www.ncbi.nlm.nih.gov/pubmed/35396928 http://dx.doi.org/10.1002/prp2.945 |
Ejemplares similares
-
Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness against COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2021) -
Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
por: Pedersen, Niels C, et al.
Publicado: (2019) -
Pharmacokinetics of Orally Administered GS-441524 in Dogs
por: Yan, Victoria C., et al.
Publicado: (2021) -
An efficient synthesis of RNA containing GS-441524: the nucleoside precursor of remdesivir
por: Moorthy, Ramkumar, et al.
Publicado: (2021) -
Advantages of the Parent Nucleoside GS-441524 over
Remdesivir for Covid-19 Treatment
por: Yan, Victoria C., et al.
Publicado: (2020)